Department of Gynaecology and Obstetrics, Assistance Publique des Hôpitaux de Paris (APHP), Jean Verdier Hospital, Avenue du 14 Juillet, 93140, Bondy, France.
Breast and Gynaecologic Cancer Registry of Côte d'Or, Epidemiology and Quality of Life Research Unit, Georges-François Leclerc Comprehensive Cancer Centre-UNICANCER, 1 rue du Professeur Marion, 21000, Dijon, France.
Breast Cancer Res Treat. 2023 Jan;197(2):377-385. doi: 10.1007/s10549-022-06807-w. Epub 2022 Nov 23.
The prognosis of local invasive recurrence (LIR) after prior carcinoma in situ (CIS) of the breast has not been widely studied and existing data are conflicting, especially considering the specific prognosis of this entity, compared to de novo invasive breast cancer (de novo IBC) and with LIR after primary IBC.
We designed a retrospective study using data from the specialized Côte d'Or Breast and Gynecological cancer registry, between 1998 and 2015, to compare outcomes between 3 matched groups of patients with localized IBC: patients with LIR following CIS (CIS-LIR), patients with de novo IBC (de novo IBC), and patients with LIR following a first IBC (IBC-LIR). Distant relapse-free (D-RFS), overall survival (OS), clinical, and treatment features between the 3 groups were studied.
Among 8186 women initially diagnosed with IBC during our study period, we retrieved and matched 49 CIS-LIR to 49 IBC, and 46 IBC-LIR patients. At diagnosis, IBC/LIR in the 3 groups were mainly stage I, grade II, estrogen receptor-positive, and HER2 negative. Metastatic diseases at diagnosis were higher in CIS-LIR group. A majority of patients received adjuvant systemic treatment, with no statistically significant differences between the 3 groups. There was no significant difference between the 3 groups in terms of OS or D-RFS.
LIR after CIS does not appear to impact per se on survival of IBC.
乳腺癌癌前原位（CIS）后局部浸润性复发（LIR）的预后尚未得到广泛研究，现有的数据存在矛盾，尤其是与新发浸润性乳腺癌（de novo IBC）和原发性 IBC 后 LIR 相比，考虑到这种实体的特定预后。
我们使用专门的科多尔乳房和妇科癌症登记处的数据，设计了一项回顾性研究，该研究于 1998 年至 2015 年进行，旨在比较 3 组局部 IBC 患者的结局：CIS 后 LIR（CIS-LIR）患者、新发 IBC（de novo IBC）患者和首次 IBC 后 LIR（IBC-LIR）患者。研究了 3 组患者之间的远处无复发生存（D-RFS）、总生存（OS）、临床和治疗特征。
在我们的研究期间，在 8186 名最初诊断为 IBC 的女性中，我们检索并匹配了 49 名 CIS-LIR、49 名 IBC 和 46 名 IBC-LIR 患者。在诊断时，3 组的 IBC/LIR 主要为 I 期、II 级、雌激素受体阳性和 HER2 阴性。在 CIS-LIR 组中，诊断时转移性疾病更高。大多数患者接受了辅助全身治疗，3 组之间无统计学差异。3 组之间的 OS 或 D-RFS 无显著差异。
CIS 后 LIR 本身似乎不会影响 IBC 的生存。
Zotero 插件